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The relationship 
between 18F‑FDG‑PETCT‑derived 
tumour metabolic activity, 
nutritional risk, body composition, 
systemic inflammation and survival 
in patients with lung cancer
Ross D. Dolan1,5*, John D. Maclay2,5, Tanvir Abbass1, David Colville3, Fatema Buali1, 
Nicholas MacLeod4, Stephen T. McSorley1, Paul G. Horgan1 & Donald C. McMillan1
The aim of this study was to examine the relationship between PET‑CT derived tumour glucose uptake 
as measured by maximum standard glucose uptake (SUVmax) and total lesion glycolysis (TLG), 
nutritional risk as measured by the malnutrition universal screening tool (MUST), CT derived body 
composition as measured by skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD), 
the systemic inflammatory response as measured by the modified Glasgow prognostic score (mGPS) 
and the neutrophil to lymphocyte ratio (NLR) and survival in patients with lung cancer, treated 
with radiotherapy. In a retrospective cohort study, 119 patients were included in final analyses. The 
majority of patients were over 65 (86%), female (52%), had a performance status (ECOG‑PS) of 0 or 1 
(57%), were at nutritional risk (57%), were overweight (53%), had visceral obesity (62%), had a normal 
SMI (51%), had a low SMD (62%) and were systemically inflammed (mGPS 1/2, 51%). An elevated TLG 
was associated with sex (p < 0.05), TNM stage (p < 0.001), MUST (p < 0.01) and mGPS (p < 0.01). An 
elevated mGPS was associated with age (p < 0.05), NLR (p < 0.01), MUST (p < 0.01), and TLG (p < 0.01). 
On univariate survival analysis, TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p ≤ 0.001), 
Low SMD (p < 0.05), SUVmax (p ≤ 0.001) and TLG (p < 0.001) were associated with overall survival. On 
multivariate survival analysis MUST (HR: 1.49 95%CI 1.12–01.98 p < 0.01) and TLG (HR: 2.02 95%CI 
1.34–3.04 p = 0.001) remained independently associated with survival. In conclusion, elevated tumour 
metabolic activity was associated with more advanced stage, greater nutritional risk, the systemic 
inflammatory response and poorer survival but not body composition analysis in patients with lung 
cancer. These results suggest that detrimental body composition is not directly determined by tumour 
metabolic activity but rather an ongoing systemic inflammatory response.
Cancer remains one of the leading causes of mortality worldwide and is responsible for approximately 8.8 mil-
lion deaths per  year1. Overall, it has been estimated that one in three people will develop cancer in their lifetime, 
and one in four will die from  it23. Globally, lung cancer is the most common cancer type and is responsible for 
1.69 million deaths per  year1. In the UK lung cancer is the 3rd most common cancer accounting for 13% of all 
new cancer  cases4.
Patients with lung cancer have long been recognized to be at nutritional risk. A widely used method of 
assessing nutritional risk is the Malnutrition Universal Screening Tool (MUST) which is a five-step screening 
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tool to identify adults who are malnourished and at risk of  malnutrition5. The relationship between CT defined 
body composition and outcomes in patients with lung cancer has been widely  reported6. Loss of skeletal muscle 
quantity as measured by skeletal muscle index (SMI) and quality as measured by skeletal muscle density (SMD) 
have both been shown to directly relate to patient morbidity, response to treatment and  survival7–10. However, the 
basis of the progressive nutritional and functional decline (often termed cachexia) in these patients is not clear. 
Historically, this cachexia was considered to be due to the increased metabolic activity of the tumour (including 
the micro environment). More recently cachexia has been considered as part of disease related malnutrition 
with  inflammation11. However, there have been few studies directly comparing tumour and host factors on loss 
of skeletal muscle in patients with cancer.
It is now possible to examine the metabolic activity of lung tumours with total lesion glycolysis (TLG) using 
clinically available Positron Emission Tomography (PET) to examine the uptake of glucose using the tracer 18F-2-
fluoro-2-deoxy-d-glucose (18FDG)12. This PET technique, based on the uptake of glucose and combined with 
CT scanning gives both metabolic and anatomic assessment of the tumour and  metastases13. PET-CT scanning 
is used extensively in patients with cancer including lung cancers in clinical decision making as it is widely used 
to assess disease extent; particularly when other imaging modalities are equivocal. In addition, a recent system-
atic review by Dolan and co-workers showed that PET-CT tumour metabolic measurements were prognostic in 
patients with cancer including lung  cancer14.
In the last decade it has become clear that the systemic inflammatory response (SIR) has prognostic value 
in both operable and advanced lung  cancer15,16. In addition, the importance of the systemic inflammatory 
response as a unifying mechanism for weight loss, loss of lean tissue and poor outcomes in patients with cancer 
is increasingly  recognised17–19. Indeed, it has been reported that SMI and SMD are inversely associated with 
measures of the systemic inflammatory response such as the neutrophil lymphocyte ratio (NLR) and modified 
Glasgow Prognostic Score (mGPS)9,20–26. The NLR is a direct comparative ratio created by dividing the level of 
neutrophils by lymphocytes from the differential white blood cell count. The mGPS is a cumulative prognostic 
score constructed from the widely accepted cut of values of > 10 mg/L for CRP and < 35 g/L for albumin. Both 
the NLR and mGPS have been shown to be prognostic in patients with both operable and inoperable  cancers15,16.
Since both TLG and mGPS have prognostic value, it is of interest that in a recent systematic review there 
was a direct relationship between both tumor and bone marrow 18FDG uptake and the systemic inflammatory 
 response14. This suggests a potential mechanism of action for the multi-systemic effects of the systemic inflam-
matory response in patients with  cancer27. Therefore, it may be hypothesised that high tumour glucose uptake 
causes both the activation of the systemic inflammatory response and loss of skeletal muscle directly and that this 
is related to poor patient outcomes. Alternatively, it may also be hypothesised that an elevated tumour glucose 
uptake is associated with the activation of the systemic inflammatory response and this in turn stimulates the 
breakdown of skeletal muscle and that this is related to poor clinical outcomes. Therefore, the primary aim of 
the present study was to examine the relationship between imaging derived tumour glucose uptake, the systemic 
inflammatory response, nutritional risk and CT-derived body composition in patients with lung cancer. The 
secondary aim of this study was to assess the impact of these factors on outcomes including survival in patients 
with lung cancer.
Material and methods
Patients. All patients with clinically confirmed non metastatic lung cancer treated with radical radiotherapy 
in North Glasgow between June 2008 and December 2012, who also underwent staging CT and 18F FDG-
PETCT imaging prior to their treatment at the Beatson Oncology Centre, Glasgow were included in the study. 
All patients were staged using the 7th edition of TNM  staging28. The dose of radiotherapy varied from 5420 to 
6400 cGy with the most common dose being 5500 cGy (62%) and 5400 cGy (35%). Patients had routine blood 
sampling including a full blood count, serum C-reactive protein (CRP) and albumin concentration at the time of 
their staging scan. Patients were followed up for 5 years or until death. Ethical approval for this study was granted 
Greater Manchester East Research Ethics Committee (Rec number: 17/NW/0190). All aspects of this study were 
performed in accordance with the Declaration of Helsinki.
Methods. Data were collected prospectively in a database, anonymised and subsequently analyzed including 
patient demographics, clinicopathological, oncological and radiological data. Body composition CT scan analy-
sis (Dolan RD and Buali F) and 18F FDG-PETCT scan analysis (Colville D) were performed retrospectively by 
clinicians blinded to clinical outcomes and markers of systemic inflammatory response. Visceral obesity (VO), 
low SMI (sarcopenia) and low SMD (myosteatosis) were recorded as measures of body composition and meas-
ured PET-CT parameters included maximum standardised tumour uptake value (SUVmax), mean standardized 
tumour uptake (SUVmean) and metabolic tumour volume (MTV)26,29. Tumour derived glucose uptake was then 
calculated as total lesion glycolysis (TLG) using the following formula: TLG = SUVmean ×  MTV14,29.
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; Abbot Diagnostics, 
Maidenhead, UK) with a lower detectable limit of 0.2 mg/L as was serum albumin (normal range 35–50 g/L). 
Differential blood cell counts were conducted as per local protocols with neutrophil and lymphocyte counts based 
on those previously  reported30. The modified Glasgow Prognostic Score (mGPS) was calculated in patients for 
whom serum CRP and albumin concentrations were  available31. The neutrophil lymphocyte ratio (NLR) was 
calculated for each patient for whom neutrophil and lymphocyte counts were available and thresholds were 
created as previously  reported32.
Body composition CT analysis. CT images were obtained at the level of the third lumbar vertebra as 
previously  described20,33. Patients who had scans 3 months or more prior to starting radiotherapy were excluded 
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from the study. Scans were excluded if they had significant movement artefacts or were missing region of 
 interest33. Each image was analysed using Image J (NIH version 1.47, https ://rsbwe b.nih.gov/ij/)20,33.
Region of interest measurements were made of visceral fat, subcutaneous fat, and skeletal muscle areas  (cm2) 
using standard Hounsfield Unit (HU) ranges (adipose tissue − 190 to − 30, and skeletal muscle − 29 to + 150)20,33. 
These were then normalised for  height2 to create indices; total fat index (TFI,  cm2/m2), subcutaneous fat index 
(SFI,  cm2/m2), visceral fat index (VFI,  cm2/m2), and skeletal muscle index (SMI,  cm2/m2)20,33. Skeletal muscle 
radiodensity (SMD, HU) was measured from the same region of interest used to calculate SMI, as its mean 
 HU20,33. Visceral obesity was defined by Doyle and colleagues as a visceral fat area > 160 cm2 for male patients 
and > 80 cm2 for female  patients34. Sarcopenia was defined by Martin and colleagues as an SMI of < 43 cm2/m2 if 
BMI < 25 kg/m2 and SMI < 53 cm2/m2 if BMI ≥ 25 kg/m2 in male patients and SMI < 41 cm2/m2 if BMI < & ≥ 25 
kg/m2 in female  patients35. Myosteatosis was defined by Martin and colleagues as an SMD < 41HU in patients 
with BMI < 25 kg/m2 and < 33HU in patients with BMI ≥ 25 kg/m35.
Measurements were carried out by two researchers (Dolan RD) and (Buali F). Inter-rater reliability was 
assessed in 30 test patient images using inter-class correlation coefficients (Total fat area = 1.000, Subcutaneous 
fat area = 1.000, Visceral fat area = 1.000, Skeletal muscle area = 0.986, Skeletal muscle density = 0.974). Investiga-
tors were blind to patient’s demographic and clinico-pathological status.
18F FDG‑PETCT . 18F FDG-PETCT scanning was performed in accordance with departmental standard 
procedures based on the EANM  guidelines36 on one of the two multimodality PETCT scanners (Discovery-690 
or 710, General Electric System, Milwaukee, WI, USA). Patients were fasted for 6 h prior to and 1 h after the IV 
injection of 400 MBq 18F-FDG29. The level of blood glucose was measured before 18F-FDG injection to guar-
antee concentrations < 11 mmol/l. Initial unenhanced CT images were acquired using a 120 kV automatic mA 
modulation range of 15–240 mAs29. The torso CT covered from the skull base to the mid-thigh and was recon-
structed at 2.5 mm  increments29. This was followed by PET images, encompassing the same transverse field of 
view as the CT. PET acquisition time was 3–4 min per bed  position29. PET attenuation correction was based on 
the CT data and images were corrected for scatter and iteratively reconstructed using Time of Flight and SharpIR 
on a 192 × 192  matrix29.
PETCT images were analysed on GE Advantage Workstation using a SUVmax of 7 g/ml threshold level to 
view the PET  images29. SUVmean and MTV were obtained from 3D isocontour at 42% of the maximal pixel 
value (VOL42)29. TLG was calculated according to the following formula: TLG = SUVmean × MTV. PETCT data 
were measured from the region of interest (ROI) placed over the dominant  sites14,29.
Statistical analysis. ROC curve analysis determined the optimum thresholds for SUVmax and TLG. Body 
composition and PET-CT measurements were presented as median and range and compared using Mann–
Whitney or Kruskal–Wallis  tests26,33,37. Categorical variables were analysed using χ2 test for linear-by-linear 
association, or χ2 test for 2 by 2  tables26,33,37.
Univariate and multivariate survival data were analysed using Cox’s proportional hazards  model26,33. Vari-
ables associated with overall survival at a significance level of p < 0.1 on univariate analysis were included in 
multivariate modeling using backward conditional regression where a two-sided p value < 0.05 was considered 
statistically  significant26,33. Overall survival was defined as time from date of 18F FDG-PETCT to date of death 
due to any  cause26,33. P values < 0.05 were considered statistically  significant26,33. Statistical analysis was performed 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA)26,33.
Ethical approval. Ethical approval for this study was granted Greater Manchester East Research Ethics 
Committee (Rec number: 17/NW/0190). These was a retrospective observational cohort study with no change 
in patient management. As a result, informed consent was not required in accordance with ethical approval. 
However, as per standard clinical practice in Greater Glasgow and Clyde informed consent to take part in clinical 
research was taken prior to commencing radiotherapy. All aspects of this study were performed in accordance 
with the Declaration of Helsinki.
Results
In total, 251 patients were identified as having undergone potentially curative radiotherapy for lung cancer. Of 
these, 61 were excluded due to scanning taking place more than 3 months before commencing radiotherapy. 
A further 71 patients were excluded due to the absence of markers of the systemic inflammatory response, CT 
derived body composition measurements or a histological diagnosis of small cell lung cancer (SCLC). A total of 
119 patients (57 males, 62 females) were included in final analyses. The relationship between clinicopathological 
characteristics, tumour activity, body composition, markers of the systemic inflammatory response and overall 
survival are shown in Table 1. The majority of patients were over 65 (86%), female (52%), had a performance 
status (ECOG-PS) of 0 or 1 (57%), were at nutritional risk (57%), were overweight (53%), had visceral obesity 
(62%), had a normal SMI (51%), had a low SMD (62%) and were systemically inflammed (mGPS 1/2, 51%). All 
patients were treated with radiotherapy, six patients received additional chemotherapy with two received con-
current chemoradiotherapy. The majority of patients had an elevated TLG (61%) and on follow-up, 107 (90%) 
patients died and the median survival was 22 months (range 3–91 months). On univariate survival analysis, TNM 
stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), Low SMD (p < 0.05), SUVmax (p < 0.01) and TLG (p < 0.001) 
were associated with overall survival (Table 1).
The relationship between the tumour metabolic activity as measured by TLG (≤ 68.89/ > 68.89) and clinico-
pathological characteristics in patients lung cancer are shown in Table 2. TLG was significantly associated with 
sex (p < 0.05), TNM stage (p < 0.001), mGPS (p < 0.01), and survival (p < 0.01).
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Table 1.  The relationship between clinicopathological characteristics, tumour activity, body composition, 
markers of the systemic inflammatory response and overall survival in patients with lung cancer. TNM 
Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, mGPS 
modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal 
Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal 
Muscle Density, TLG Total Lesion Glycolysis, SUVmax Standardised Tumour Uptake Value, TLG Total Lesion 
Glycolysis.
Characteristics n = 119 (%) Univariate Cox regression analysis OS p-value
Sex
Male 57 (47.9) 1.34 (0.91–1.97) 0.141
Female 62 (52.1)
Age
< 65 17 (14.3) 1.04 (0.79–1.37) 0.768
65–74 54 (45.4)
> 75 48 (40.3)
TNM
I 42 (35.3) 1.40 (1.12–1.74) 0.003
II 22 (18.5)
III 55 (46.2)
ECOG-PS
0/1 68 (57.1) 0.74 (0.50–1.09) 0.126
≥ 2 51 (42.9)
Inflammatory response
mGPS
 0 58 (48.7) 1.30 (1.06–1.61) 0.014
 1 20 (16.8)
 2 41 (34.5)
NLR
< 3 53 (44.5) 1.38 (1.09–1.76) 0.009
3–5 35 (29.4)
> 5 31 (26.1)
MUST
Low risk 51 (42.9) 1.60 (1.21–2.11) 0.001
Intermediate risk 52 (43.7)
High risk 16 (13.4)
Body composition
BMI kg/m2
 <25 56 (47.1) 0.77 (0.54–1.13) 0.182
≥ 25 63 (52.9)
Visceral obesity
VFA 134.23 (14.35–577.08) 1.00 (0.99–1.01) 0.780
Visceral obesity
No 45 (37.8) 0.81 (0.55–1.20) 0.292
Yes 74 (62.2)
Sarcopenia
SMI 44.23 (29.40–74.36) 1.00 (0.98–1.02) 0.899
Low SMI
No 61 (51.3) 0.98 (0.67–1.44) 0.930
Yes 58 (48.7)
Myosteatosis
SMD 34.53 (9.58–51.24) 1.03 (1.00–1.05) 0.043
Low SMD
No 45 (37.8) 0.66 (0.44–0.97) 0.035
Yes 74 (62.2)
PET-CT analysis
SUVmax 14.60 (3.10–36.9.) 1.03 (1.01–1.06) 0.010
SUVmax > 11.40
No 44 (37.0) 2.05 (1.34–3.14) 0.001
Yes 75 (63.0)
TLG 102.66 (3.47–2070.90) 1.01 (1.00–1.02) < 0.001
TLG > 68.89
No 47 (29.5) 2.18 (1.46–3.26) < 0.001
Yes 72 (60.5)
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The relationship between the systemic inflammatory response as measured by mGPS and clinicopathological 
characteristics in patients lung cancer are shown in Table 3. An elevated mGPS was associated with age (p < 0.05), 
NLR (p < 0.01), MUST (p < 0.01) and TLG (p < 0.01).
Table 2.  The relationship between TLG and clinicopathological characteristics in patients with lung cancer. 
TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, mGPS 
modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal 
Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal 
Muscle Density, TLG Total Lesion Glycolysis.
Characteristics Low TLG (n = 47) High TLG (n = 72) p-value
Sex
Male 29 (61.7) 28 (38.9) 0.015
Female 18 (38.3) 44 (61.1)
Age
< 65 5 (10.60 12 (16.7) 0.578
65–74 21 (44.7) 33 (45.8)
> 75 21 (44.7) 27 (37.5)
TNM
I 27 (57.4) 15 (20.8) < 0.001
II 8 (17.0) 14 (19.4)
III 12 (25.5) 43 (59.7)
ECOG-PS
0/1 28 (59.6) 40 (55.6) 0.665
≥ 2 19 (40.4) 32 (44.4)
Inflammatory response
mGPS
 0 31 (66.0) 27 (37.5) 0.006
 1 7 (14.9) 13 (18.1)
 2 9 (19.1) 32 (44.4)
NLR
< 3 26 (55.3) 27 (37.5) 0.146
3–5 12 (25.5) 23 (31.9)
> 5 9 (19.1) 22 (30.6)
MUST
Low risk 29 (61.7) 22 (30.6) 0.003
Intermediate risk 15 (31.9) 37 (51.4)
High risk 3 (6.4) 13 (18.1)
Body composition
BMI kg/m2
< 25 19 (40.4) 37 (51.4) 0.241
 ≥ 25 28 (59.6) 35 (48.6)
Visceral obesity
VFA 128.94 (15.33–577.08) 140.19 (14.35–549.90) 0.683
Visceral obesity
No 17 (36.2) 28 (38.9) 0.765
Yes 30 (63.8) 44 (61.1)
SMI 43.34 (29.43–66.36) 45.35 (29.40–74.36) 0.350
Low SMI
No 24 (51.1) 37 (51.4) 0.972
Yes 23 (48.9) 35 (48.6)
SMD 31.80 (9.58–48.04) 35.31 (13.98–51.24) 0.098
Low SMD
No 15 (31.9) 30 (41.7) 0.284
Yes 32 (68.1) 42 (58.3)
Survival
Survival rate (3 year)
 No 26 (55.3) 58 (80.6) 0.003
 Yes 21 (44.7) 14 (19.4)
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Table 3.  The relationship between mGPS and clinicopathological/PET-CT characteristics in patients with lung 
cancer. TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, 
mGPS modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal 
Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal 
Muscle Density, TLG Total Lesion Glycolysis.
Characteristics mGPS 0 (n = 58) mGPS 1 (n = 20) mGPS 2 (n = 41) p-value
Sex
Male 36 (62.1) 7 (35.0) 14 (34.1) 0.617
Female 22 (37.9) 13 (65.0) 27 (65.9)
Age
< 65 10 (17.2) 4 (20.0) 3 (7.3) 0.011
65–74 25 (43.1) 9 (45.0) 20 (48.8)
> 75 23 (39.7) 7 (35.0) 18 (43.9)
TNM
I 23 (39.7) 8 (40.0) 11 (26.8) 0.695
II 11 (19.0) 3 (15.0) 8 (19.5)
III 24 (41.4) 9 (45.0) 22 (53.7)
ECOG-PS
0/1 32 (55.2) 13 (65.0) 23 (56.1) 0.735
≥ 2 26 (44.8) 7 (35.0) 18 (43.9)
Inflammatory response
NLR
 < 3 35 (60.3) 6 (30.0) 12 (29.3) 0.002
 3–5 17 (29.3) 6 (30.0) 12 (29.3)
 > 5 6 (10.3) 8 (40.0) 17 (41.5)
MUST
Low risk 30 (51.7) 11 (55.0) 10 (24.4) 0.007
Intermediate risk 25 (43.1) 7 (35.0) 20 (48.8)
High risk 3 (5.2) 2 (10.0) 11 (26.8)
Body composition
BMI kg/m2
 < 25 25 (43.1) 8 (40.0) 23 (56.1) 0.348
 ≥ 25 33 (56.9) 12 (60.0) 18 (43.9)
Visceral obesity
VFA 122.56 (21.73–549.90) 140.19 (46.71–577.08) 148.45 (14.35–433.30) 0.770
Visceral obesity
No 19 (32.8) 7 (35.0) 19 (46.3) 0.374
Yes 39 (67.2) 13 (65.0) 22 (53.7)
SMI 43.87 (29.40–72.04) 43.80 (29.43–74.36) 44.66 (34.70–73.49) 0.675
Low SMI
No 29 (50.0) 11 (55.0) 21 (51.2) 0.928
Yes 29 (50.0) 9 (45.0) 20 (48.8)
SMD 33.23 (13.98–51.24) 36.65 (9.58–49.96) 35.18 (16.81–49.25) 0.312
Low SMD
No 18 (31.0) 9 (45.0) 18 (43.9) 0.330
Yes 40 (69.0) 11 (55.0) 23 (56.1)
PET-CT analysis
TLG 64.01 (3.47–912.18) 115.77 (5.15–968.76) 227.40 (10.82–2070.90) < 0.001
TLG > 68.89
No 31 (53.4) 7 (35.0) 9 (22.0) 0.006
Yes 27 (46.6) 13 (65.0) 32 (78.0)
Survival
Survival rate (3 year)
 No 37 (63.8) 16 (80.0) 31 (75.6) 0.267
 Yes 21 (36.2) 4 (20.0) 10 (24.4)
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The relationship between clinicopathological characteristics, tumour activity, body composition, markers 
of the systemic inflammatory response and overall survival in patients with lung cancer is shown in Table 4. 
On univariate survival analysis, TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p ≤ 0.001), Low 
SMD (p < 0.05), SUVmax (p ≤ 0.001) and TLG (p < 0.001) were associated with overall survival. On multivariate 
survival analysis MUST (HR:1.49, 95%CI 1.12–1.98, p < 0.01), and TLG > 68.89 (HR:2.02, 95%CI 1.34–3.04, 
p < 0.001) remained independently associated with overall survival.
Table 4.  The relationship between clinicopathological characteristics, tumour activity, body composition, 
markers of the systemic inflammatory response and overall survival in patients with lung cancer: Univariate 
and multivariate analysis. TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group 
Performance Status, mGPS modified Glasgow Prognostic Score, MUST Malnutrition Universal Screening Tool, 
BMI Body Mass Index, SMI Skeletal Muscle Index, SMD Skeletal Muscle Density, TLG Total Lesion Glycolysis.
Characteristics n = 119 (%) Univariate Cox regression analysis OS p-value
Multivariate Cox regression analysis 
OS p-value
Sex
Male 57 (47.9) 1.34 (0.91–1.97) 0.141 – –
Female 62 (52.1)
Age
< 65 17 (14.3) 1.04 (0.79–1.37) 0.768 – –
65–74 54 (45.4)
> 75 48 (40.3)
TNM
I 42 (35.3) 1.40 (1.12–1.74) 0.003 – 0.329
II 22 (18.5)
III 55 (46.2)
ECOG-PS
0/1 68 (57.1) 0.74 (0.50–1.09) 0.126 – –
≥ 2 51 (42.9)
Inflammatory response
mGPS
 0 58 (48.7) 1.30 (1.06–1.61) 0.014 – 0.326
 1 20 (16.8)
 2 41 (34.5)
MUST
Low risk 51 (42.9) 1.60 (1.21–2.11) 0.001 1.49 (1.12–1.98) 0.006
Intermediate risk 52 (43.7)
High risk 16 (13.4)
Body composition
BMI kg/m2
 < 25 56 (47.1) 0.77 (0.54–1.13) 0.182 – –
 ≥ 25 63 (52.9)
Visceral obesity
No 45 (37.8) 0.81 (0.55–1.20) 0.292 – –
Yes 74 (62.2)
Sarcopenia
Low SMI
 No 61 (51.3) 0.98 (0.67–1.44) 0.930 – –
  Yes 58 (48.7)
Myosteatosis
Low SMD
 No 45 (37.8) 0.66 (0.44–0.97) 0.035 – 0.192
Y es 74 (62.2)
PET-CT analysis
TLG > 68.89
 No 47 (29.5) 2.18 (1.46–3.26) < 0.001 2.02 (1.34–3.04) 0.001
 Yes 72 (60.5)
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Discussion
The results of the present study show that, in a cohort of patients with lung cancer undergoing radical radiother-
apy, there was a significant association between TLG (metabolic activity) and the mGPS (systemic inflammatory 
response) and both were significantly associated with nutritional risk and survival. However, neither TLG nor 
mGPS was significantly associated with CT derived body composition. Therefore, in this cross sectional study it 
is clear that elevated tumour metabolic activity and the systemic inflammatory responses are directly linked but 
their comparative link to body composition (in particular skeletal muscle mass) requires further investigation.
The results of the present study are consistent with a recent systematic review which reported a relationship 
between markers of the systemic inflammatory response and PET-CT  parameters14. However, there was not 
a significant association between either TLG or mGPS and SMI (skeletal muscle mass). The former relation-
ship has not, to our knowledge, been previously examined in cancer patients. However, the latter relationship 
between an elevated systemic inflammatory response and low SMI has been reported  repeatedly38. Therefore, it 
may be that, given that approximately 50% of patients had a low SMI, the present study was too small to detect 
a differential effect of TLG and mGPS on low SMI. Further work on larger cancer datasets will be required to 
determine whether there is indeed a differential effect.
Although the results of the present study do confirm the relationship between TLG and measures of the 
systemic inflammatory response. The mechanism by which a metabolically active tumour evokes a systemic 
inflammatory response is not clear. However, in the absence of data on the relationship between an elevated TLG 
and detailed tumour phenotypying, there are a number of plausible mechanisms. Tumour hypoxia and necrosis 
and the subsequent production of lactate result in the local activation of innate immune cells and production of 
pro-inflammatory cytokines, including interleukin-6 (IL-6), stimulating production of  CRP39,40. Circulating IL-6 
levels are linked to tumour necrosis and both local and systemic inflammatory responses in patients undergoing 
resection for colorectal  cancer39. An alternative hypothesis is that circulating tumour cells activate myeloid cells 
in the bone marrow to produce such pro-inflammatory cytokines, in particular IL-640. Indeed, there is some 
evidence from PET-CT studies that there is increased uptake of glucose from the bone marrow and that the 
SUVmax from the bone marrow is also associated with markers of the systemic inflammatory  response14. In the 
present study, glucose uptake was only examined in the bulk tumour. Irrespective, both of these mechanisms 
would, in turn, result in a progressive catabolic state with subsequent breakdown of skeletal muscle resulting in 
cancer related cachexia. 
The results of the present study are also consistent with the proposal of McAllister and Weinberg that the 
systemic inflammatory response is the tip of the cancer iceberg reflecting tumour/host immune cytokine activ-
ity, disordered metabolism and the development of cancer associated symptoms such as loss of appetite, fatigue 
and poor physical  function41–43. Given the present results and the increasing importance of the inflammatory 
responses in the assessment and treatment of lung cancer, it will also be of considerable interest to better define 
the relationship between tumour metabolic activity and the components of the tumour microenvironment 
including tumour inflammatory cell  infiltrate44,45, the tumour  stroma46,47 and tumour mutational burden meas-
ured with circulating tumour DNA .
The present study had a number of limitations including that the data was retrospectively analysed from 
a prospective audit of clinical practice, the majority of patients were treated with radiotherapy in isolation 
(97%). This study predates the SOCCAR study of 2014, therefore standard practice was for patients to receive 
radiotherapy initially followed by chemotherapy depending on their physiological  reserve48. As a result, just six 
patients received combined chemo and radiotherapy. Also, histological tumour type was not determined in 21% 
of cases due to concurrent comorbidities and therefore the present cohort may be a relatively heterogeneous 
group. However, the present study also has a number of strengths. To our knowledge, this is the first study to 
comprehensively examine the nature of the relationship between tumour metabolic activity, body composition, 
the systemic inflammatory response and survival in patients with cancer. The measurements were carried out 
within one month of each other and the sample size compares favourably to previous studies in the  field14. Indeed, 
given the routine clinical measurements used in the present study these results could be readily validated to give 
a new insight into these relationships in patients with cancer.
The results showing a relationship between the systemic inflammatory response and tumour metabolic activity 
but not between tumour metabolic activity and CT-derived body composition have some important implications 
for ongoing patient care. These results suggest that targeting the systemic inflammatory response with the use 
of anti-inflammatory agents could potentiate the effectiveness of treatments directly targeting the tumour such 
as surgery or curative  radiotherapy40. In this way the incorporation of modulation of the systemic inflammatory 
response may have a profound impact on patient care moving forward.
In conclusion, in patients with lung cancer treated with radical radiotherapy, tumour glucose uptake was 
associated with activation of systemic inflammatory response and mortality but not lower skeletal muscle mass.
Conclusion
In patients with lung cancer treated with radical radiotherapy, tumour glucose uptake was associated with activa-
tion of systemic inflammatory response and mortality but not lower skeletal muscle mass.
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